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COX-2 has been inappropriately overexpressed in various human malignancies, and is considered as one of the representative tar-
gets for the chemoprevention of inflammation-associated cancer. In order to assess the role of COX-2 in colitis-induced carcinogen-
esis, the selective COX-2 inhibitor celecoxib and COX-2 null mice were exploited in an azoxymethane (AOM)-initiated and dextran 
sulfate sodium (DSS)-promoted murine colon carcinogenesis model. The administration of 2% DSS in drinking water for 1 week after 
a single intraperitoneal injection of AOM produced colorectal adenomas in 83% of mice, whereas only 27% of mice given AOM alone 
developed tumors. Oral administration of celecoxib significantly lowered the incidence as well as the multiplicity of colon tumors. The 
expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and 
DSS, and this was inhibited by celecoxib administration. Likewise, celecoxib treatment abrogated the DNA binding of NF-κB, a key 
transcription factor responsible for regulating expression of aforementioned pro-inflammatory enzymes, which was associated with 
suppression of IκBα degradation. In the COX-2 null (COX-2–/–) mice, there was about 30% reduction in the incidence of colon tu-
mors, and the tumor multiplicity was also markedly reduced (7.7 ± 2.5 vs. 2.43 ± 1.4, P < 0.01). As both pharmacologic inhibition and 
genetic ablation of COX-2 gene could not completely suppress colon tumor formation following treatment with AOM and DSS, it is 
speculated that other pro-inflammatory mediators, including COX-1 and iNOS, should be additionally targeted to prevent inflamma-
tion-associated colon carcinogenesis.
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INTRODUCTION
Patients with inflammatory bowel disease (IBD) face an 
increased lifetime risk of developing colorectal cancer (CRC). 
Although early detection and appropriate removal of polyps 
represent essential components for the prevention of sporadic 
CRC, intervention with an efficient anti-inflammatory strategy 
may provide the better opportunity in the management of the 
colitis-associated cancer [1-3]. 
 While normal colonic mucosa does not express COX-2, this 
enzyme is abnormally upregulated during the colorectal 
carcinogenesis in an ‘adenoma-carcinoma’ or an 
‘inflammation-dysplasia-carcinoma’ sequence [4]. As aberrant 
COX-2 overexpression accelerates carcinogenesis by 
stimulating cell proliferation and rendering cancerous cells 
resistant to apoptosis, COX-2 inhibition has been considered 
to be a rational strategy for the chemoprevention of CRC. In 
line with this notion, offsprings from COX-2 null mice mated 
to ApcΔ716 mutant mice exhibited an 86% reduction in the 
number of polyps compared to those from the ApcΔ716 control 
littermates [5]. Further data from epidemiologic, animal, and 
clinical studies indicate that non-steroidal anti-inflammatory 
drugs (NSAIDs) with COX-2 inhibitory activities are capable 
of preventing intestinal polyposis or CRC [6,7]. 
 However, other studies have revealed that COX-2 may 
have a negligible or even an opposite effect on colon 
inflammation and possibly, carcinogenesis. Both myeloid cell- 
and endothelial cell-specific COX-2 knockout mice exhibited 
an increase in experimentally induced colitis and decreased 
epithelial cell proliferation when compared with control 
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littermates [8]. Thus, COX-2 expression in myeloid cells 
and endothelial cells may play a role in protecting epithelial 
cells in this murine colitis model. Moreover, pharmacologic 
inhibition of the COX-2 function exacerbates symptoms in 
patients with colitis [9] and in rats [10]. Notably, the disruption 
of COX-1 (Ptgs1) in the mouse attenuated gastrointestinal 
abnormalities, whereas COX-2 (Ptgs2) null mice showed 
reproductive anomalies and defects in kidney development 
[11,12]. These findings suggest that the current COX-2 
targeted strategy for the purpose of cancer prevention is not 
necessarily valid and may need to be reconsidered. With 
regards to the controversy on the role of COX-2 in colorectal 
carcinogenesis, Ishikawa and Herschman [13] concluded 
that the mechanism underlying colitis-associated colon 
cancer formation in mice might differ from that for hereditary 
and sporadic CRCs in humans, suggesting the possible 
involvement COX-2-independent mechanisms.
 In the current study, we attempted to evaluate the chemo-
preventive effects of pharmacological inhibition and genetic 
ablation of COX-2 in the azoxymethane (AOM)-initiated 
and dextran sulfate sodium (DSS)-promoted intestinal 
tumorigenesis in mice, an experimental model that mimics 
the human colitis-associated CRC.
MATERIALS AND METHODS 
Animals and reagents 
Male Institute of Cancer Research (ICR) mice (Daehan 
Biolink Experimental Animal Center, Daejeon, Korea) five 
to six week of age and the COX-2+/+ and COX-2–/– mice of 
C57BL/6J3129/Ola genetic background [11,12,14] were 
maintained at the Animal Facility of Seoul National University 
according to the Institutional Animal Care guidelines. All 
animal experiments were conducted on protocols approved 
by the Institutional Animal Care and Use Committee at Seoul 
National University (SNU-060616-2). After the adaptation for 
7 days, the mice were randomly assigned to treatment and 
control groups. All animals were housed in plastic cages (four 
mice/cage) with free access to drinking water and a pelleted 
basal diet, CRF-1 (Purina Co., Ltd., Tokyo, Japan), under 
climate-controlled quarters (24°C at 50% humidity) with a 
12-hour light-12 hour dark cycle. AOM was purchased from 
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). DSS with 
a molecular weight of 36 to 50 kDa was obtained from MP 
Biochemicals, Inc. (Solon, OH, USA) and dissolved in distilled 
water at a concentration of 2% (w/v). Celecoxib suspended 
in 0.5% carboxymethyl cellulose (CMC) was given to mice by 
gastric intubation. 
Development of colon tumors in mice
Male ICR mice were divided into 7 groups (Fig. 1) for use 
in a colitis-associated murine carcinogenesis experiment 
[15]. Group 1 mice were given a vehicle only, Group 2 mice 
treated with 2% DSS alone in drinking water for 7 days, 
Group 3 mice treated with a single intraperitoneal (i.p.) dose 
(10 mg/kg) of AOM, and Group 4 mice given a single i.p. 
injection of AOM followed by 2% DSS in the drinking water 






















AOM (10 mg/kg, i.p.)
DSS (2% in drinking water)
Vehicle (0.5% CMC)
Celecoxib (0.1 or 0.25 mg/kg, p.o.)
Figure 1. Experimental schedule for 
inducing colitis-induced adenomas 
in  mice.  AOM, azoxymethane; 
DSS, dextran sulfate sodium; i.p., 
intraperitoneal; p.o., per oral.
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evaluating the effect of celecoxib treatment; Group 5 same 
as Group 4 treated additionally with 0.5% CMC alone served 
as a control group, Group 6 given 0.1 mmole/kg celecoxib 
orally for 14 weeks, and Group 7 was given 0.25 mmole/kg 
celecoxib for 14 weeks. To further verify the role of COX-2 in 
the AOM-initiated and DSS-promoted carcinogenesis [15], 
we compared the incidence and the multiplicity of AOM plus 
DSS-induced colon carcinogenesis between COX-2 wild-type 
and COX-2 knockout mice [11,14]. After 16 weeks, all mice 
were sacrificed by cervical dislocation for further analysis. 
Histopathological evaluation 
The extracted colon tissue was spread onto a plastic 
sheet, fixed in 10% formalin for 16 hours, and prepared for 
paraffin block. The paraffin sections were subjected to the 
hematoxylin and eosin (H&E) staining to assess the severity 
of histopathological colitis. Colon cancer cells associated with 
ulcerative colitis was verified microscopically by a pathologist. 
The tumor incidence and the multiplicity were calculated by 
the following formulae; tumor incidence (%) = (number of 
tumor-bearing mice / total number of mice) × 100 and tumor 
multiplicity = number of tumors / number of tumor-bearing 
mice.
Mast cell staining and counting 
The paraffin-embedded sections were deparaffinized with 
xylene and stained with 0.5% toluidine blue in acetate buffer 
(pH 4.0). Staining with acidic toluidine blue gave rise to 
a light blue background, which permitted mapping of the 
metachoronic mast cells with purplish blue-staining granules 
in their cytoplasm in relation to the other tissue components 
within the specimen. To count the mast cells, these sections 
were examined under a microscope with × 100 or × 400 
magnification, and a grid eyepiece (0.0625 mm2) was placed 
over the cross-sectional area of tissues. 
Western blot analysis 
The colon tissue was collected, placed immediately in liquid 
nitrogen and pulverized in a mortar. The pulverized colon 
tissue was homogenized in ice-cold lysis buffer (150 mM 
NaCl, 0.5% Triton-X 100, 50 mM Tris-HCl [pH 7.4], 20 mM 
EGTA, 1 mM dithiothreitol [DTT], 1 mM Na3VO4 and protease 
inhibitor cocktail tablet [Roche Molecular Biochemicals, 
Mannheim, Germany]). Lysates were centrifuged at 13,000 
×g for 20 minutes, and aliquots of supernatant containing 40 
mg proteins were boiled in SDS sample loading buffer for 5 
minutes before electrophoresis on 12% SDS-PAGE. After 
transfer to polyvinylidene fluoride membrane, the blots were 
blocked with 5% fat-free dried milk-PBS containing 0.1% 
Tween 20 (PBST) buffer for 2 hours at room temperature and 
then washed in PBST buffer. The membranes were incubated 
for 12 hours at 4°C with 1 : 1,000 dilutions of primary 
antibodies for COX-1 (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), COX-2 (Cayman, Ann Arbor, MI, USA), 
and inducible nitric oxide synthase (iNOS; BD Biosciences, 
Franklin Lakes, NJ, USA). Blots were washed three times 
with PBST at 5 minutes intervals, incubated in a solution 
containing 1 : 5,000 dilution of horseradish peroxidase-
conjugated secondary antibody for 1 hour and then washed 
again in PBST for three times. The transferred proteins were 
visualized with an enhanced chemiluminescence detection kit 
(Amersham Biosciences, Buckinghamshire, UK) according to 
the manufacturer’s instructions.
Reverse transcription-PCR analysis 
Total RNA was isolated from the harvested colon tissue 
by appropriate treatment using the TRIzol® reagent (Life 
Technologies, Milan, Italy) and 2 mg of total RNA was reverse 
transcribed by Moloney murine leukemia virus reverse 
transcriptase according to the manufacturer’s instructions 
(Promega, Madison, WI, USA). PCR was performed by using 
the Primix Ex Taq Kit (Takara, Chiba, Japan) with specific 
primers. The PCR reaction was preformed at respective 
thermal cycles of 1 minute at 95°C for denaturation and 1 
minute at 72°C for annealing. Amplification products were 
resolved on 1.2% agarose gel, stained with ethidium bromide 
and photographed under UV light.
Preparation of nuclear extracts 
For the preparation of nuclear and cytosolic extracts from 
mouse colon, the tissue was collected, placed immediately 
in liquid nitrogen and pulverized in a mortar. The pulverized 
colon tissue was homogenized in ice-cold hypotonic buffer 
A (10 mM HEPES [pH7.8], 10 mM KCl, 2 mM MgCl2, 1 
mM DTT, 0.1 mM EDTA, 0.1 mM phenylmethylsulfonyl 
fluoride [PMSF]). After 20 minutes incubation on ice, the 
nuclear fraction was separated from the cytosolic fraction by 
centrifugation for 5 minutes at 12,000 ×g. The collected nuclei 
were washed once with 400 mL of buffer A plus 25 mL of 10% 
NP-40, centrifuged for 2 minutes at 12,000 ×g, and then 
resuspended in 150 mL of buffer C (50 mM HEPES [pH 7.8], 
50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 
mM PMSF and 10% glycerol). The supernatant containing 
nuclear proteins was collected by centrifugation for 15 
minutes at 12,000 ×g and stored at –80°C after determination 
of protein concentrations. 
Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay was performed using 
a DNA-protein binding detection kit (Gibco BRL, Grand 
Island, NY, USA) according to the manufacturer’s protocol. 
Briefly, the NF-κB oligonucleotide probe (5’-AGT TGA GGG 
GAC TTT CCC AGG C-3’) was labeled with [g-32P] ATP by 
T4 polynucleotide kinase and purified on a Nick column 
(Amersham Pharmacia Biotech, Piscataway, NJ, USA). The 
binding reaction was carried out in a total volume of 25 mL 
containing 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM 
DTT, 1 mM EDTA, 4% (v/v) glycerol, 0.1 mg/mL sonicated 
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salmon sperm DNA, 10 mg of nuclear extracts, and 100,000 
cpm of the labeled probe. After 50 minutes incubation at 
room temperature, 2 mL of 0.1% bromophenol blue was 
added, and samples were electrophoresed through a 6% 
non-denaturating PAGE at 150 V in a cold room for 2 hours. 
Finally, the gel was dried and exposed to an X-ray film. 
Gelatin zymography 
Gelatin gels (7.5%) were prepared according to the standard 
procedure. For preparing the running gel, gelatin stock 
solution (20 mg/mL in double-distilled H2O) was diluted to get 
the concentration of 0.2%. For this procedure, the Bio Rad 
Mini Protean II electrophoresis apparatus was used. During 
gel solidification, colon tissue protein samples (typically 10-
25 mg) were mixed with Tris-glycine SDS sample buffer (2 
× 0.5 M Tris-HCl [pH 6.8], glycerol, 10% SDS and 0.1% 
bromophenol blue in diluted with deionized water) and then 
stand for 10 minutes at room temperature. Colon tissue 
samples were added to wells and then electrophoresed in 1 × 
Tris-glycine SDS running buffer (125 mM Tris-HCl [pH 8.3], 
1.23 M glycine and 0.5% SDS) according to the standard 
running conditions. After running, the zymogram renaturing 
buffer (10 × 25% Triton X-100 in double distilled water] was 
diluted with deionized water (1 : 9, v/v), and the gel was 









































































































































Figure 2. Footprints of inflammation in azoxymethane (AOM)-initiated and dextran sulfate sodium (DSS)-promoted colitis-associated carcinogenesis. 
Mice given a single intraperitoneal dose of AOM (10 mg/kg) followed by exposure to 2% DSS in drinking developed colon tumors. (A) Mast cells were 
identified by tryptase immunostaining and counted. A statistically significant (***P < 0.001) increase of mast cells was noted in tumor tissues of the 
AOM plus DSS treated group (× 400 magnification). (B) Tissue levels of TNF-α. *Significantly different from the value of the control group (P < 0.05). 
(C, D) Expression of representative tissue matrix metalloproteinases (MMPs). The expression of MMPs was measured by reverse transcription-
PCR. (D) The catalytic activity of MMPs was assessed by the Gelatin zymography as described in Materials and Methods. (E-G) Serum levels of 
interleukin (IL)-6, TNF-α, and nitric oxide (NO). Significantly higher levels of IL-6, TNF-α, and NO were noted in AOM + DSS group, suggesting 
inflammation contributed to colitic cancer. The experimental details are described in the Materials and Methods. GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase; MW, molecular weight.
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incubated in the buffer (100 mL for one or two mini-gels) with 
gentle agitation for 30 minutes at room temperature. After 
incubation, the zymogram renaturing buffer was decanted 
and replaced with 1 × zymogram developing buffer (Tris-
base, Tris-acid, NaCl, and CaCl2). The gel was equilibrated 
for 30 minutes at room temperature with gentle agitation 
and replaced in the fresh 1 × zymogram developing buffer. 
After overnight incubation at 37°C, the product was stained 
for 30 minutes in the staining buffer (Coomassie Blue 
R-250, methanol, acetic acid and distilled water). Gels were 
destained with an appropriate Coomassie R-250 destaining 
solution (methanol : acetic acid : water [50 : 10 : 40, v/v]). 
Areas of protease activity appeared as clear bands against a 
dark blue background where the protease had digested the 
substrate.
Statistical analysis 
Results are expressed as the means ± SD. Data were 
analyzed by one-way ANOVA and Student’s t-test. 
RESULTS
Involvement of inflammatory mediators in DSS-
promoted colon carcinogenesis 
In our previous studies, administration of a single i.p. dose of 
AOM (10 mg/kg) alone caused colon tumor formation in about 
15% of treated mice with an average number of 1.7 tumors 
per mouse, while administration of 2% DSS alone in drinking 
water for 7 consecutive days failed to induce colon tumor 
formation. However, the administration of AOM followed by 
DSS in drinking water resulted in the 84% incidence of colon 
tumors (21 mice among 25 mice developed colon tumors) 
with the average number of 7.16 ± 2.7 tumors per mouse. 
Macroscopically, nodular, polypoid or caterpillar-like tumors 
were observed mostly in the middle and distal colon of 
animals treated with AOM plus DSS. 
 In order to determine whether DSS-induced colitis 
promoted colon carcinogenesis induced by AOM, we 
counted the number of mast cells. Mast cells are tissue-























































Figure 3. (A, B) Upregulation of COX-2 in colitis-associated cancer as determined by (A) reverse transcription-PCR for COX-2 mRNA or (B) Western 
blot analysis for COX-2 protein in colonic tissues. Expression of COX-2 as well as its mRNA transcript was significantly increased in the colon of 
azoxymethane (AOM) plus dextran sulfate sodium (DSS) treated mice compared to the mice in the vehicle group. (C) Comparison of the relative 
expression of COX-2 and COX-1 and their mRNA transcripts between the vehicle group and the AOM plus DSS group. (D) Immunohistochemical 
staining of COX-2. Aberrantly increased expression of COX-2 was observed in infiltrated inflammatory cells and some epithelial cells surrounding the 
tumor (× 100). GAPDH, glyceraldegyde-3-phosphate dehydrogenase.
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in inflammatory reactions [16]. The infiltration of mast cells 
has been considered to be associated with IBD [17] and 
inflammation-associated colon tumors [15,18]. Proportion of 

























































































































































Figure 4. Effects of the COX-2 inhibitor celecoxib on azoxymethane (AOM) plus dextran sulfate sodium (DSS)-induced colon carcinogenesis and pro-
inflammatory signaling. Mice were treated with a single intraperitoneal injection of AOM and/or subsequent administration of 2% DSS in drinking water for 
7 weeks. Control animals were given the vehicle alone. Celecoxib (0.1 mmole/kg or 0.25 mg/kg) was given orally by gastric intubation for 14 weeks. (A, 
B) Tumor incidences and tumor multiplicities. (C) The expression of COX-2 and inducible nitric oxide synthase (iNOS) in the colon of mice measured by 
Western blot analysis elevated. (D) DNA binding activity of NF-κB determined by the gel shift assay as described in Materials and Methods. (E) Inhibitory 
effects of celecoxib administration on IκBα degradation induced by AOM and DSS. The expression of IκBα was measured by Western blot analysis.
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plus DSS-treated mice compared with the normal colonic 
mucosa (Fig. 2A). Since mast cells represent an important 
source of TNF-α, which is implicated in the pathogenesis 
of IBD, we measured the levels of this cytokine in colonic 
mucosa. As illustrated in Figure 2B, there was a significant 
increase in the colonic TNF-α production in mice treated with 
AOM plus DSS. 
 Enhanced expression and secretion of matrix metallo-
proteinases (MMPs) are essential for tumor invasion and 
metastasis [19]. Compared with the normal distal colon, the 
AOM plus DSS-treated colon exhibited markedly elevated 
expression of some MMPs, such as MMP2, MMP9, MMP13, 
and MT2-MMP (Fig. 2C) as well as their catalytic activities 
determined by zymography (Fig. 2D). In addition, the 
serum levels of TNF-α, interleukin-6, and nitric oxide were 
significantly increased in the AOM plus DSS-treated mice 
(Fig. 2E-2G). 
Upregulation of COX-2 expression in colitis-
associated cancer
Inappropriately elevated expression of COX-2 has been 
implicated in pathogenesis of inflammation-associated 
malignancies including colitic cancer [12,20]. COX-2 
expression was significantly increased at both transcriptional 
(Fig. 3A) and translational (Fig. 3B) levels in the AOM plus 
DSS-treated group compared to the vehicle-treated control 
group. Repeated experiments showed a significant difference 
in the colonic COX-2 expression between the control and 
the AOM plus DSS-treated animals, with the ratio of COX-
2/COX-1 mRNA and protein expression 2.3- and 6.7-fold 
higher, respectively in the colitis promoted tumors (Fig. 3C). 
By immunohistochemical staining, aberrantly enhanced 
expression of COX-2 was observed in infiltrated inflammatory 
cells and some epithelial layers of the colon tumor (Fig. 3D). 
AOM + DSS



















Figure 5. (A) Effects of celecoxib 
on expression of matrix metallo-
proteinases (MMPs) and (B) their 
activity in the colon tumors of mice 
treated with azoxymethane (AOM) 
and dextran sulfate sodium (DSS). 
GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase.
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Effect of pharmacologic COX-2 inhibition 
on AOM-initiated and DSS-promoted colon 
carcinogenesis
The findings that COX-2 was overexpressed in colitis-
associated carcinogenesis prompted us to determine 
whether a pharmacologic inhibition of this pro-inflammatory 
enzyme could prevent DSS-promoted colon carcinogenesis. 
Oral administration of celecoxib (0.25 mmole/kg) for 14 
consecutive weeks resulted in substantial reduction (83.3% 
vs. 44.4%) in the incidence (Fig. 4A) and the multiplicity (6.00 
± 2.75 vs. 1.75 ± 0.96 tumors/mouse, P < 0.01; Fig. 4B) of 
colon tumor formation induced by AOM plus DSS. Compared 
with colonic mucosa in control mice, the colonic tumor 
tissues from mice treated with AOM and DSS displayed 
markedly elevated COX-2 expression (Fig. 4C). The level of 
the house keeping-enzyme COX-1 remained unchanged. 
The oral administration of celecoxib inhibited the AOM plus 
DSS-induced expression of COX-2 and also iNOS, another 
prototypic pro-inflammatory enzyme, in a dose-dependent 
manner (Fig. 4C). 
 NF-κB regulates the expression of COX-2 and iNOS, 
and promotes inflammation-associated tumorigenesis [21]. 
Therefore, we determined whether celecoxib could suppress 
the activation of this transcription factor in the colon tissue 
of mice treated with AOM plus DSS. Under physiologic 
conditions, NF-κB is sequestered in the cytoplasm by forming 
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Figure 6. Effects of genetic ablation of COX-2 on azoxymethane (AOM)-initiated and dextran sulfate sodium (DSS)-promoted colon carcinogenesis. (A) 
Gross pictures showing coloitis-induced cancer and histological examination of colonic tissues by H&E staining in COX-2+/+ and COX-2–/– mice. (B, C) 
Comparison of (B) the tumor incidence and (C) the multiplicity of tumors formed in the colon of COX-2+/+ and COX-2–/– mice.
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an inactive complex with IκBα protein. Upon exposure of 
cells to pro-inflammatory stimuli, IκBα translocation rapid 
phosphorylation and degradation. This allows release of 
NF-κB and translocation to the nucleus, where it binds to 
the promoter regions of target genes including COX-2 and 
thereby regulates their transcription [22]. Nuclear extracts 
from colonic mucosa of mice treated with AOM and DSS 
displayed the pronounced NF-κB DNA binding as assessed 
by the gel shift assay (Fig. 4D). Neither AOM nor DSS alone 
induced the DNA binding activity of NF-κB. Celecoxib dose-
dependently inhibited AOM and DSS-induced DNA binding 
of NF-κB. Addition of 100 × excess cold probe of NF-κB 
negated the NF-κB DNA binding (Fig. 4D). AOM plus DSS 
treatment led to marked degradation of cytoplasmic IκBα 
(Fig. 4E), which accounts for the increased NF-κB DNA 
binding. Celecoxib treatment dose-dependently restored 
the IκBα level. Moreover, celecoxib inhibited upregulation 
of MMP-2, -9, and MT2-MMP induced by AOM plus DSS 
(Fig. 5A). Celecoxib treatment also suppressed the catalytic 
activities of MMPs, especially gelatinases represented by 
MMP-2 and -9 (Fig. 5B).
Effects of genetic disruption of COX-2 on 
AOM-initiated and DSS-promoted colon 
carcinogenesis
Besides the pharmacologic inhibition of COX-2 by a selective 
inhibitor, we determined whether ablation of COX-2 gene 
could inhibit colitis-associated colon carcinogenesis. When 
the AOM-induced and DSS-promoted colon carcinogenesis 
was compared in COX-2 wild type and knockout mice, the 
number and the size of tumors were much smaller in COX-
2–/– mice than in COX-2+/+ mice (Fig. 6A). There were severe/
thick dysplastic lesions, infiltration, and low-grade dysplasia in 
the colon of AOM plus DSS treated wild type (COX-2+/+) mice.
 In COX-2 wild-type littermates (C57BL6 background), 
a single i.p. injection of AOM (10 mg/kg) followed by 1 
week exposure to administration of 2% DSS in drinking 
water resulted in the 100% incidence of colon tumors with 
an average tumor multiplicity of 7.7 ± 2.5 tumors/mouse, 
whereas a 70% tumor incidence with an average of 2.43 ± 
1.4 tumors in COX-2–/– mice (Fig. 6B and 6C). 
DISCUSSION
In line with the findings that COX-2 expression is substantially 
increased in inflamed mucosa and further elevated in 
dysplastic and cancerous lesions [23], COX-2 inhibition by 
NSAIDs has been chemopreventive in familial or sporadic 
CRC [24,25]. In accord with results of our present study, 
celecoxib was proven to be effective in the prevention of 
colitis-associated tumorigenesis in a murine model of human 
IBD. We also found that COX-2 deficient mice were less 
susceptible than the wild-type mice to AOM-initiated and 
DSS-promoted colon carcinogenesis. Nonetheless, both 
pharmacologic inhibition and genetic ablation of COX-2 could 
achieve only a modest level of cancer prevention, indicative 
of COX-2-independent or other molecular mechanisms 
underlying colitis-induced carcinogenesis [26,27]. These 
include modulation of alternative eicosanoid pathways 
(e.g., 5-lipoxygenase, COX-1, etc.) and upstream signaling 
cascade changes (e.g., cytosolic phospholipase A2) [20] as 
well as iNOS-mediated promotion. As COX-1 also produces 
some pro-inflammatory prostaglandins with oncogenic 
potential, we speculate that this house keeping enzyme may 
also contribute to the development of CRC. In support of 
this supposition, the COX-1 selective inhibitor, mofezolac, 
protected against intestinal carcinogenesis in Apc gene 
knockout mice [28]. Notably, the combined treatment with 
both COX-1 and COX-2 selective inhibitors was found to 
be more effective in suppressing polyp growth than each 
inhibitor alone [29]. Therefore, an agent capable of inhibiting 
both COX-1 and COX-2 with no or minimal gastrointestinal 
toxicity, if any, could be developed as a better candidate for 
the prevention of colitis-associated cancer.
 Celecoxib and some selective COX inhibitors prescribed 
for the treatment of arthritis, have been tested in human 
chemoprevention trials [30]. However, long-term use of 
COX-2 selective coxib drugs has caused some adverse 
effects on the cardiovascular system and unsatisfactory 
responsiveness. While short-term administration of celecoxib 
markedly inhibited adenoma growth in animal tumor models, 
uninterrupted long-term celecoxib administration to APCMin/+ 
mice, though initially regressed bowel tumors, resulted in 
gradual recurrence of tumors to the levels comparable to 
those attained in untreated controls [31]. As a plausible 
explanation for such contradictory results, celecoxib 
treatment may initially suppress COX-2 expression and 
prostaglandin E2 (PGE2) production, but a long-term use 
may produce paradoxically elevated levels of this molecule 
and reactivate PGE2-associated growth factor signaling 
pathways in either tumor or normal tissues [31]. This may 
explain why selective inhibition of COX-2 is only partially 
protective against colitis-induced CRC, and gradually become 
ineffective. Thus, celecoxib resistance appears to occur 
as a consequence of an acquired adaptation to changes 
in the crypt microenvironment associated with chronic 
intestinal inflammation and impaired acute wound-healing 
responsiveness [31]. 
 It has also been reported that COX-2 deletion in myeloid 
and endothelial cells, but not in epithelial cells, exacerbates 
DSS-induced murine colitis and exhibited greater weight 
loss, increased clinical scores, and decreased epithelial cell 
proliferation than control littermates [8]. Such dual functions 
of COX-2 may account for a double-edged nature of NSAIDs 
[32]. Thus, it is likely that selective COX-2 inhibition is not 
necessarily satisfactory for the prevention of colitis-associated 
carcinogenesis, and coordinated targeting of COX together 
with other pro-inflammatory molecules should be considered 
36   J Cancer Prev 25(1):27-37, March 30, 2020
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in order to better achieve CRC chemoprevention.
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